Heart disease remains the number one leading cause of death year after year. The increased risk factors are certainly related to cardiovascular conditions but are also significantly attributable to metabolic and autoimmune diseases. There are significant advances in cardiovascular interventions, but the metabolic and autoimmune side is only just beginning. Statins are and have been the most popular intervention for high cholesterol and other lipids. If we look closely at the lipoproteins that are affected by statins, there are two in particular that stand out: the APO-A and APO-B lipoproteins. These lipoproteins can completely change the way we’re translating important biomarkers such as: cholesterol, triglycerides, HDL’s and LDL’s. These key lipoproteins are made in the enterocyte of the colon and synthesized in the liver. If this isn’t supported by a healthy microbiome and balanced immune system, it’s clear to see how cardiac issues can arise from these disease states. The key to a healthy heart is through the microbiome and the immune system. Diet and exercise are mandatory treatments to add to the protocol, but what is the intervention to prevent future degradation? In this advanced course, we will uncover how GLP-1 Agonists will be to the future of treating cardiovascular disease– through the microbiome and immune systems.
- Review how metabolic and autoimmune diseases contribute to the number one leading cause of death – cardiovascular disease
- Summarize what are GLP-1 Agonists and how do they work in the microbiome and autoimmune systems
- Describe how GLP-1 Agonists compare to other popular drugs such as Metformin, Statins, and other popular pharmaceuticals